CA2623181A1 - Reagents, methods and kits for selection of anti-fungal therapy for candida species fung i - Google Patents
Reagents, methods and kits for selection of anti-fungal therapy for candida species fung i Download PDFInfo
- Publication number
- CA2623181A1 CA2623181A1 CA002623181A CA2623181A CA2623181A1 CA 2623181 A1 CA2623181 A1 CA 2623181A1 CA 002623181 A CA002623181 A CA 002623181A CA 2623181 A CA2623181 A CA 2623181A CA 2623181 A1 CA2623181 A1 CA 2623181A1
- Authority
- CA
- Canada
- Prior art keywords
- probe
- reagent
- fluconazole
- nucleic acid
- fungi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 62
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 34
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 43
- 230000000843 anti-fungal effect Effects 0.000 title claims description 32
- 241000222120 Candida <Saccharomycetales> Species 0.000 title description 29
- 239000000523 sample Substances 0.000 claims abstract description 237
- 241000233866 Fungi Species 0.000 claims abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 15
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 82
- 229960004884 fluconazole Drugs 0.000 claims description 82
- 229940079593 drug Drugs 0.000 claims description 59
- 239000003814 drug Substances 0.000 claims description 59
- 238000009396 hybridization Methods 0.000 claims description 42
- 150000007523 nucleic acids Chemical group 0.000 claims description 41
- 241000235645 Pichia kudriavzevii Species 0.000 claims description 30
- 241000222173 Candida parapsilosis Species 0.000 claims description 27
- 229940121375 antifungal agent Drugs 0.000 claims description 25
- 241000222122 Candida albicans Species 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 241000222178 Candida tropicalis Species 0.000 claims description 22
- 108010020326 Caspofungin Proteins 0.000 claims description 22
- 238000001514 detection method Methods 0.000 claims description 22
- 230000002538 fungal effect Effects 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 21
- 229960003034 caspofungin Drugs 0.000 claims description 21
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 19
- 230000000295 complement effect Effects 0.000 claims description 18
- 238000007901 in situ hybridization Methods 0.000 claims description 13
- 230000008685 targeting Effects 0.000 claims description 12
- 230000003321 amplification Effects 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 11
- 229960004740 voriconazole Drugs 0.000 claims description 11
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 10
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 10
- 239000002853 nucleic acid probe Substances 0.000 claims description 10
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 9
- 229960003942 amphotericin b Drugs 0.000 claims description 9
- 230000000903 blocking effect Effects 0.000 claims description 9
- 238000003752 polymerase chain reaction Methods 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 7
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 7
- 241000222126 [Candida] glabrata Species 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 125000006850 spacer group Chemical group 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 238000001228 spectrum Methods 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000007834 ligase chain reaction Methods 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 229940095731 candida albicans Drugs 0.000 claims description 3
- 208000032343 candida glabrata infection Diseases 0.000 claims description 3
- 229940055022 candida parapsilosis Drugs 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 238000001668 nucleic acid synthesis Methods 0.000 claims description 3
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims description 3
- 238000003753 real-time PCR Methods 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 108010066717 Q beta Replicase Proteins 0.000 claims description 2
- 108020001027 Ribosomal DNA Proteins 0.000 claims description 2
- 238000006073 displacement reaction Methods 0.000 claims description 2
- 238000012296 in situ hybridization assay Methods 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 108020004418 ribosomal RNA Proteins 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000004243 sweat Anatomy 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 abstract description 6
- 241000894007 species Species 0.000 description 55
- 244000197813 Camelina sativa Species 0.000 description 18
- 229920000642 polymer Polymers 0.000 description 12
- 206010040047 Sepsis Diseases 0.000 description 11
- 208000037815 bloodstream infection Diseases 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 241001508813 Clavispora lusitaniae Species 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 7
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 6
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- NJBRNNOGZPVNNR-UHFFFAOYSA-N 1-[[2-(2,4-difluorophenyl)oxiran-2-yl]methyl]-1,2,4-triazole;methanesulfonic acid Chemical compound CS(O)(=O)=O.FC1=CC(F)=CC=C1C1(CN2N=CN=C2)OC1 NJBRNNOGZPVNNR-UHFFFAOYSA-N 0.000 description 5
- 206010017533 Fungal infection Diseases 0.000 description 5
- 244000285963 Kluyveromyces fragilis Species 0.000 description 5
- 241000235048 Meyerozyma guilliermondii Species 0.000 description 5
- 208000031888 Mycoses Diseases 0.000 description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 description 5
- 239000000370 acceptor Substances 0.000 description 5
- 239000003429 antifungal agent Substances 0.000 description 5
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 description 5
- 229950004154 ravuconazole Drugs 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 4
- 206010017523 Fungaemia Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- -1 candins Chemical compound 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QEVGZEDELICMKH-UHFFFAOYSA-N Diglycolic acid Chemical compound OC(=O)COCC(O)=O QEVGZEDELICMKH-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940062768 amphotericin b liposomal Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960000730 caspofungin acetate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000023077 detection of light stimulus Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IWBOPFCKHIJFMS-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl) ether Chemical compound NCCOCCOCCN IWBOPFCKHIJFMS-UHFFFAOYSA-N 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 238000012295 fluorescence in situ hybridization assay Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000006357 methylene carbonyl group Chemical group [H]C([H])([*:1])C([*:2])=O 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- OGUJBRYAAJYXQP-IJFZAWIJSA-N vuw370o5qe Chemical compound CC(O)=O.CC(O)=O.C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 OGUJBRYAAJYXQP-IJFZAWIJSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71915305P | 2005-09-20 | 2005-09-20 | |
| US60/719,153 | 2005-09-20 | ||
| US78965606P | 2006-04-05 | 2006-04-05 | |
| US60/789,656 | 2006-04-05 | ||
| PCT/US2006/036645 WO2007035814A2 (en) | 2005-09-20 | 2006-09-20 | Reagents, methods and kits for classification of fungi and direction of anti-fungal therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2623181A1 true CA2623181A1 (en) | 2007-03-29 |
Family
ID=37889500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002623181A Abandoned CA2623181A1 (en) | 2005-09-20 | 2006-09-20 | Reagents, methods and kits for selection of anti-fungal therapy for candida species fung i |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20070082351A1 (enExample) |
| EP (1) | EP1945810B1 (enExample) |
| JP (1) | JP5356819B2 (enExample) |
| AU (1) | AU2006292174B2 (enExample) |
| CA (1) | CA2623181A1 (enExample) |
| WO (1) | WO2007035814A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2636664T3 (es) | 2008-09-02 | 2017-10-06 | The Governing Council Of The University Of Toronto | Microelectrodos nanoestructurados y dispositivos de biodetección que los incorporan |
| EP3467487A1 (en) | 2011-01-11 | 2019-04-10 | The Governing Council Of The University Of Toronto | Protein detection method |
| WO2012109157A2 (en) | 2011-02-07 | 2012-08-16 | The Governing Council Of The University Of Toronto | Bioprobes and methods of use thereof |
| JP5990987B2 (ja) * | 2012-04-11 | 2016-09-14 | 株式会社Ihi | 微生物固定方法、および微生物検出方法 |
| WO2015077632A1 (en) | 2013-11-21 | 2015-05-28 | Avails Medical, Inc. | Electrical biosensor for detecting a substance in a bodily fluid, and method and system for same |
| US9963733B2 (en) | 2014-06-05 | 2018-05-08 | Avails Medical, Inc. | Devices, systems and methods for detecting viable infectious agents in a fluid sample |
| JP6978408B2 (ja) | 2015-08-25 | 2021-12-08 | アバイルズ メディカル，インコーポレイテッド | 流体試料中の生存微生物を検出する装置、システムおよび方法 |
| FR3044415B1 (fr) * | 2015-11-27 | 2017-12-01 | Biomerieux Sa | Procede de determination de la reaction d'un microorganisme a son exposition a un antibiotique |
| WO2017132095A1 (en) | 2016-01-25 | 2017-08-03 | Avails Medical, Inc. | Devices, systems and methods for detecting viable infectious agents in a fluid sample using an electrolyte-insulator-semiconductor sensor |
| EP4397973A3 (en) | 2016-05-31 | 2024-09-04 | Avails Medical, Inc. | Devices, systems and methods to detect viable infectious agents in a fluid sample and susceptibility of infectious agents to anti-infectives |
| WO2018111234A1 (en) | 2016-12-13 | 2018-06-21 | Avails Medical, Inc. | DEVICES, SYSTEMS AND METHODS TO DETECT THE PRESENCE OF ß-LACTAM ANTIBIOTIC HYDROLYZING BACTERIA IN A SAMPLE |
| WO2019005296A1 (en) | 2017-06-27 | 2019-01-03 | Avails Medical, Inc. | APPARATUS, SYSTEMS AND METHODS FOR DETERMINING THE SENSITIVITY OF MICROORGANISMS TO ANTI-INFECTIOUS |
| WO2019070739A1 (en) | 2017-10-03 | 2019-04-11 | Avails Medical, Inc. | APPARATUSES, SYSTEMS AND METHODS FOR DETERMINING THE CONCENTRATION OF MICROORGANISMS AND THE SENSITIVITY OF MICROORGANISMS TO ANTI-INFECTIOUS, BASED ON OXIDOREDUCTION REACTIONS |
| ES3042508T3 (en) | 2017-12-05 | 2025-11-21 | Avails Med Inc | Preparing an output sample comprising a defined concentration of an infectious agent for downstream testing |
| EP3846940A4 (en) | 2018-09-03 | 2022-07-27 | Visby Medical, Inc. | DEVICES AND METHODS FOR TESTING ANTIBIOTIC SUSCEPTIBILITY |
| EP3861357A4 (en) | 2018-10-04 | 2022-11-09 | First Light Diagnostics, Inc. | Test cartridges |
| WO2020117650A1 (en) | 2018-12-03 | 2020-06-11 | Avails Medical, Inc. | Apparatus, systems, and methods for quantifying infectious agents |
| US11352675B2 (en) * | 2020-01-03 | 2022-06-07 | Visby Medical, Inc. | Devices and methods for antibiotic susceptability testing |
| CN112458145B (zh) * | 2021-01-06 | 2021-06-04 | 健康元海滨药业有限公司 | 一种注射用醋酸卡泊芬净制剂的无菌检测方法 |
| CN117551801A (zh) * | 2023-09-25 | 2024-02-13 | 中国医学科学院北京协和医院 | 分子标记及其应用和基于erg11基因拷贝数检测近平滑念珠菌氟康唑耐药性的方法和系统 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541308A (en) * | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
| CA2025180A1 (en) | 1989-10-12 | 1991-04-13 | William G. Weisburg | Nucleic acid probes and methods for detecting pathogenic candida yeasts |
| US5539082A (en) * | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5763169A (en) * | 1995-01-13 | 1998-06-09 | Chiron Diagnostics Corporation | Nucleic acid probes for the detection and identification of fungi |
| JP4456182B2 (ja) * | 1996-09-16 | 2010-04-28 | ザ カバメント オブ ザ ユーナイテッド ステイツ オブ アメリカ，リプリゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ，センターズ フォー ディジ | Ｃａｎｄｉｄａ ｓｐｐ．の検出のための方法および組成物 |
| DE19654946A1 (de) * | 1996-10-22 | 1998-05-07 | Univ Eberhard Karls | Verfahren zum Nachweis von resistenten Pilzzellen in klinischem Material |
| US20020098483A1 (en) | 1996-10-22 | 2002-07-25 | Jurgen Loffler | Method for detecting resistant fungal cells in clinical material |
| US6242178B1 (en) * | 1997-07-30 | 2001-06-05 | Centers For Disease Control And Prevention | Nucleic acid probes for detecting Candida species |
| EP1185702B1 (en) * | 1999-05-28 | 2017-02-08 | Fujirebio Europe N.V. | Nucleic acid probes and methods for detecting clinically important fungal pathogens |
| JP2003522535A (ja) * | 2000-02-08 | 2003-07-29 | アバンテイス・フアルマ・エス・アー | アデノウイルスの検出及び定量方法 |
| DE60136567D1 (de) * | 2000-05-01 | 2008-12-24 | Gen Probe Inc | Polynukleotid-proben zum nachweis und zur quantifizierung von candida spezies |
| DE10053821A1 (de) * | 2000-10-30 | 2002-05-08 | Univ Eberhard Karls | Detektion von seltenen Candida-Spezies |
| JP2002142775A (ja) * | 2000-11-14 | 2002-05-21 | Ss Pharmaceut Co Ltd | カンジダ属真菌検出用核酸及びそれを用いたカンジダ属真菌の検出方法 |
| AU2002257284A1 (en) * | 2001-05-18 | 2002-12-03 | Boston Probes, Inc. | Pna probes, probe sets, methods and kits pertaining to the detection of candida |
| WO2005025744A1 (en) | 2003-09-05 | 2005-03-24 | Exxonmobil Chemical Patents Inc. | Processes for formulating catalyst compositions having desirable particle size characteristics |
| WO2005054516A2 (en) * | 2003-11-26 | 2005-06-16 | Advandx, Inc. | Peptide nucleic acid probes for analysis of certain staphylococcus species |
-
2006
- 2006-09-20 WO PCT/US2006/036645 patent/WO2007035814A2/en not_active Ceased
- 2006-09-20 CA CA002623181A patent/CA2623181A1/en not_active Abandoned
- 2006-09-20 AU AU2006292174A patent/AU2006292174B2/en not_active Ceased
- 2006-09-20 EP EP06815025.9A patent/EP1945810B1/en not_active Not-in-force
- 2006-09-20 US US11/524,988 patent/US20070082351A1/en not_active Abandoned
- 2006-09-20 JP JP2008532349A patent/JP5356819B2/ja not_active Expired - Fee Related
-
2008
- 2008-10-15 US US12/288,051 patent/US8795972B2/en not_active Expired - Fee Related
-
2014
- 2014-06-26 US US14/315,696 patent/US20140342356A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1945810B1 (en) | 2015-07-01 |
| US20070082351A1 (en) | 2007-04-12 |
| US20090092994A1 (en) | 2009-04-09 |
| US8795972B2 (en) | 2014-08-05 |
| AU2006292174A1 (en) | 2007-03-29 |
| WO2007035814A8 (en) | 2015-10-08 |
| WO2007035814A2 (en) | 2007-03-29 |
| WO2007035814A3 (en) | 2008-12-24 |
| AU2006292174B2 (en) | 2012-02-23 |
| EP1945810A2 (en) | 2008-07-23 |
| EP1945810A4 (en) | 2009-07-22 |
| JP5356819B2 (ja) | 2013-12-04 |
| JP2009508531A (ja) | 2009-03-05 |
| US20140342356A1 (en) | 2014-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8795972B2 (en) | Reagents, methods and kits for classification of fungi and direction of anti-fungal therapy | |
| US6753421B2 (en) | Probes for the detection of mycobacteria | |
| CA2623736C (en) | Compositions and methods for the detection of candida species | |
| EP1709198B1 (en) | Peptide nucleic acid probes for analysis of certain staphylococcus species | |
| JP2020516271A (ja) | Ｉｌｖ３を使用した微生物の検出及び設計 | |
| US9663827B2 (en) | Molecular gram stain | |
| EP1766072B1 (en) | Hybridization of pna probes in alcohol solutions | |
| AU2006252346B2 (en) | Peptide nucleic acid probes for analysis of microorganisms | |
| EP2152906B1 (en) | Peptide nucleic acid probes for analysis of certain staphylococcus species | |
| EP2315853B1 (en) | Method for detecting and identifying candida species | |
| US20140113284A1 (en) | Differential detection and quantification of oxalobacter | |
| CN101448954A (zh) | 用于真菌分类的试剂、方法和试剂盒以及抗真菌疗法的指导 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20180717 |